Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Más filtros

Tipo del documento
Asunto de la revista
Intervalo de año de publicación
1.
J Inherit Metab Dis ; 30(6): 970-7, 2007 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-17955342

RESUMEN

UNLABELLED: Autosomal dominant hypercholesterolaemia (ADH) are a heterogeneous group of monogenic lipid disorders. The plasma level of lipoprotein(a) (Lp(a)) is a heritable trait associated with increased coronary heart disease (CHD) risk. OBJECTIVE: To evaluate the frequency of elevated Lp(a) as a cause of ADH and the characteristics of subjects with high Lp(a) (hyperLp(a)). MATERIAL AND METHODS: 200 healthy subjects and 933 unrelated Spanish subjects with a clinical diagnosis of ADH who were screened for low-density lipoprotein receptor (LDLR) and apolipoprotein B (APOB) gene mutations. Standard cardiovascular risk factors and blood lipid levels, including Lp(a), were evaluated. HyperLp(a) was defined as Lp(a) levels >or=95th centile of control values. RESULTS: Lp(a) was higher in 263 subjects without LDLR or APOB mutations (nonLDLR/nonAPOB group) than in 670 subjects with mutations (FH group): 40.0 mg/dl (interquartile range (IR) 15.0-89.0) versus 31.0 mg/dl (IR 11.0-73.7) respectively, p = 0.002. HyperLp(a) was present in 23% of ADH subjects (odds ratio (OR) 5.6 (95% CI, 2.9 to 10.7) versus controls) and 29% of nonLDLR/nonAPOB subjects (OR 7.7; 3.9 to 15.4). After adjusting for Lp(a), LDL cholesterol levels were <95th centile in 28 (10.6%) nonLDLR/nonAPOB subjects and in 9 (1.3%) FH subjects. Lp(a) levels were nonsignificantly higher in ADH subjects with early-onset CHD than in those without (43.5 mg/dl, (IR, 12.0-82.0) versus 31.7 mg/dl (11.8-76.5), respectively). CONCLUSIONS: HyperLp(a) is responsible for ADH in approximately 6% of nonLDLR/nonAPOB subjects. HyperLp(a) would not appear to be a risk factor for early-onset CHD in ADH, independently of whether genetic defects have or have not been demonstrated.


Asunto(s)
Hipercolesterolemia/diagnóstico , Hipercolesterolemia/genética , Hiperlipoproteinemias/diagnóstico , Hiperlipoproteinemias/genética , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Enfermedades Cardiovasculares/metabolismo , Estudios de Casos y Controles , Femenino , Genes Dominantes , Humanos , Lípidos/sangre , Masculino , Persona de Mediana Edad , Isoformas de Proteínas , Receptores de LDL/metabolismo , Factores de Riesgo , España
2.
Rev Neurol ; 40(3): 159-62, 2005.
Artículo en Español | MEDLINE | ID: mdl-15750901

RESUMEN

INTRODUCTION: Serotonin is a neurotransmitter synthesized from tryptophan. It is implied in the regulation of mood, cognition, sleep cycle, synthesis of cerebrospinal fluid, and other processes. Generally, it is implied in human pathology by hypofunction. However, there is a complication of unknown incidence related to treatment with drugs that increase the stimulation of 5-HT1A serotonin receptors, called serotonin syndrome (SS). Clinically, it is characterised by the presence of a triad of mental and autonomic disorders, and motor hyperactivity. This entity has not biological markers and its diagnosis could be done verifying the proposed criteria. CASE REPORTS: Two cases of SS are presented, one of them related to the combination of risperidone and sertraline, as first report in the literature. Both cases had a favourable outcome employing support measures. CONCLUSIONS: The physiopathology, the diagnosis, the differential diagnosis, and the treatment are reviewed. We emphasize the potentially high frequency of this disorder, given the growing use of serotonin activity modifying drugs, and the typically benign course of the SS once the support measures are started.


Asunto(s)
Síndrome de la Serotonina/diagnóstico , Síndrome de la Serotonina/fisiopatología , Anciano , Quimioterapia Combinada , Humanos , Masculino , Persona de Mediana Edad , Neuronas/química , Neuronas/metabolismo , Risperidona/efectos adversos , Risperidona/uso terapéutico , Serotonina/metabolismo , Antagonistas de la Serotonina/efectos adversos , Antagonistas de la Serotonina/uso terapéutico , Síndrome de la Serotonina/tratamiento farmacológico , Inhibidores Selectivos de la Recaptación de Serotonina/efectos adversos , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Sertralina/efectos adversos , Sertralina/uso terapéutico , Resultado del Tratamiento
3.
Rev Argent Microbiol ; 20(4): 201-4, 1988.
Artículo en Español | MEDLINE | ID: mdl-3073406

RESUMEN

An enzyme immunoassay, RSV-EIA Abbot, was evaluated by comparison with indirect immunofluorescence. Nasopharyngeal secretions obtained from 95 infants and young children with acute respiratory infections were examined for the presence of respiratory syncytial virus antigens with both methods. Specimens were stored at -70 degrees C before being tested by EIA. Out of 60 samples positive by indirect immunofluorescence, 46 were also positive by RSV-EIA (sensitivity 78.7%) and 34 out of 35 immunofluorescence negative specimens were negative by RSV-EIA (specificity 97.1%). Therefore, the EIA appears to be an acceptable test for the rapid detection of RSV as an alternative for indirect immunofluorescence.


Asunto(s)
Antígenos Virales/análisis , Ensayo de Inmunoadsorción Enzimática , Técnica del Anticuerpo Fluorescente , Moco/inmunología , Virus Sincitiales Respiratorios/inmunología , Infecciones por Respirovirus/inmunología , Niño , Humanos , Nasofaringe/metabolismo , Valor Predictivo de las Pruebas , Factores de Tiempo
4.
Arch Med Sci ; 6(5): 701-8, 2010 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-22419928

RESUMEN

INTRODUCTION: Hypertension and obesity are common problems among diabetic patients accelerating progression of vascular diabetic complications. MATERIALS AND METHODS: A two-stage stratified random sampling design was used, and individuals aged 15 years and over were interviewed. This cross-sectional study evaluated lipid abnormalities of 117 obese type 2 diabetic patients (28 males and 89 females), and 56 hypertensive obese type 2 diabetic patients (22 males and 34 females). Total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), very-low-density lipoprotein cholesterol (VLDL-C) and high-density lipoprotein cholesterol (HDL-C) concentrations were assayed using standard biochemical methods. RESULTS: Hypertensive obese type 2 diabetic females had significantly higher mean serum concentrations of TC (p = 0.043), TG (p = 0.046), LDL-C (p= 0.040), TC/HDL-C ratio (p = 0.001) and LDL-C/HDL-C ratio (p = 0.003) compared with hypertensive obese non-diabetic females. Similar results were found in hypertensive obese type 2 diabetic males compared with hypertensive obese non-diabetic males. Hypertensive obese type 2 diabetic females had significantly higher serum TC, TG and TC/HDL-C ratio (p < 0.05) than hypertensive obese type 2 diabetic males. Hypertensive obese type 2 diabetic females had significantly higher mean serum concentrations of TG (p = 0.03) and TC (p = 0.01) than obese type 2 diabetic females. There was a significant association between blood glucose and LDL-C concentrations in type 2 diabetic subjects (r = 0.36; p< 0.05). CONCLUSION: Obese hypertensive type 2 diabetic females are exposed more profoundly to risk factors including atherogenic dyslipidaemia compared with males.

5.
J Lab Physicians ; 2(1): 25-30, 2010 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-21814403

RESUMEN

AIMS: Previous studies have shown that diabetes mellitus (DM) increases the risk of cardiovascular diseases in females to a greater extent than in males. In this cross-sectional study, we evaluated the lipid profiles of type 2 diabetic males and females. MATERIALS AND METHODS: The study included 107 type 2 diabetic patients (41 males and 66 females), and 122 hypertensive type 2 diabetic patients (39 males and 83 females), aged 15 years and older. Total cholesterol (TC), triglycerides (TG), low density lipoprotein-cholesterol (LDL-C), very low density lipoprotein-cholesterol (VLDL-C) and high density lipoprotein-cholesterol (HDL-C) concentrations were assayed for each group using standard biochemical methods. RESULTS: The mean TC, TG, VLDL-C, HDL-C and LDL-C concentrations, TG/HDL and LDL/HDL ratios were higher in type 2 diabetic and hypertensive type 2 diabetic patients compared with non-diabetic, and hypertensive non-diabetic control subjects, although these were not significant (P > 0.05). Hypertensive type 2 diabetic females had significantly higher serum TC (7.42 ± 1.63 mmol/L) than hypertensive non-diabetic males (5.76±1.57 mmol/L; P < 0.05). All the other lipid and lipoprotein parameters except HDL-C were non-significantly higher in females with type 2 DM and those with hypertension and type 2 DM, compared with type 2 diabetic and hypertensive type 2 diabetic males, respectively (P > 0.05). CONCLUSION: This study demonstrated that dyslipidemia exists in our type 2 diabetic population with greater TC in hypertensive type 2 diabetic females compared with hypertensive type 2 diabetic males. This suggests that hypertensive type 2 diabetic females are exposed more profoundly to risk factors including atherogenic dyslipidemia compared with males.

7.
Rev. neurol. (Ed. impr.) ; 40(3): 159-162, 1 feb., 2005. tab
Artículo en Es | IBECS (España) | ID: ibc-037131

RESUMEN

Introducción. La serotonina es un neurotransmisor sintetizado a partir del triptófano que interviene en la regulación del estado anímico, los procesos cognitivos, el ciclo del sueño y la síntesis del líquido cefalorraquídeo, entre otros procesos. Su implicación en patología humana se debe, generalmente, a hipofunción. Sin embargo, existe una complicación, cuya incidencia real no se conoce, del tratamiento con fármacos que incrementan la estimulación sobre los receptores 5-HT1A de la serotonina, el síndrome serotoninérgico (SS). Desde el punto de vista clínico, se caracteriza por la presencia de una tríada consistente en alteraciones mentales, datos de disfunción autonómica e hiperactividad motora. Esta entidad no posee ningún marcador biológico, y su diagnóstico se basa en la verificación de los criterios propuestos. Casos clínicos. Se presentan dos casos de SS, uno de ellos secundario a la combinación de risperidona y sertralina, descrita por primera vez en la literatura. En ambos casos, la evolución fue favorable con el empleo de medidas de soporte. Conclusiones. Se revisan la fisiopatología, el diagnóstico, el diagnóstico diferencial y el tratamiento del SS. Se quiere destacar la alta frecuencia potencial de este trastorno, ligada al empleo cada vez mayor de fármacos modificadores de la actividad serotoninérgica, y la habitual benignidad del mismo una vez reconocido e instauradas las medidas de soporte oportunas


Introduction. Serotonin is a neurotransmitter synthesized from tryptophan. It is implied in the regulation of mood, cognition, sleep cycle, synthesis of cerebrospinal fluid, and other processes. Generally, it is implied in human pathology by hypofunction. However, there is a complication of unknown incidence related to treatment with drugs that increase the stimulation of 5-HT1A serotonin receptors, called serotonin syndrome (SS). Clinically, it is characterised by the presence of a triad of mental and autonomic disorders, and motor hyperactivity. This entity has not biological markers and its diagnosis could be done verifying the proposed criteria. Case reports. Two cases of SS are presented, one of them related to the combination of risperidone and sertraline, as first report in the literature. Both cases had a favourable outcome employing support measures. Conclusions. The physiopathology, the diagnosis, the differential diagnosis, and the treatment are reviewed. We emphasize the potentially high frequency of this disorder, given the growing use of serotonin activity modifying drugs, and the typically benign course of the SS once the support measures are started


Asunto(s)
Masculino , Anciano , Persona de Mediana Edad , Humanos , Síndrome de la Serotonina/diagnóstico , Trastorno Depresivo/tratamiento farmacológico , Citalopram/efectos adversos , Amitriptilina/uso terapéutico , Paroxetina/efectos adversos , Perfenazina/uso terapéutico , Sertralina/efectos adversos
8.
Rev. argent. microbiol ; 20(4): 201-4, oct.-dic. 1988. tab
Artículo en Español | LILACS | ID: lil-79160

RESUMEN

Un ensayo inmunoenzimático comercial Abboutt-RSV-EIA fue evaluado comprarándolo con la inmunofluorescencia indirecta. Aspirados nasofaríngeos de 95 niños con infección respiratoria aguda baja fueron procesados por inmunofluorescencia y por enzimoinmunoensayo para revelar la presencia de antígenos del virus respiratorio sincicial. De los 60 materiales positivos por inmunofluorescencia, 46 también lo fueron por enzimoinmunoensayo (sensibilidad 78,7%); de 35 negativos, 34 fueron también negativos por el Abbout-RSV-EIA (especificidad 97,1%). Según los resultados presentados, la evaluada es aceptable como una alternativa para el diagnóstico rápido de VRS en lugares donde no se cuente con otros recursos


Asunto(s)
Niño , Humanos , Antígenos Virales/análisis , Moco/inmunología , Virus Sincitiales Respiratorios/inmunología , Infecciones por Respirovirus/inmunología , Ensayo de Inmunoadsorción Enzimática , Técnica del Anticuerpo Fluorescente , Nasofaringe/metabolismo , Valor Predictivo de las Pruebas , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA